Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies - Wikidata - awgldk - TriplyDB

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

http://www.wikidata.org/entity/Q34231261

about

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models Oncogene withdrawal engages the immune system to induce sustained cancer regression.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.

P2860

Q27026544-D76BE3C1-C677-4AB2-ADF8-BDE3285D3D41 Q33578960-999C084A-C9EA-4214-970D-7BE2A2A9273F Q33987633-B64B6CA4-B66F-4193-BA29-6F85A90A3C66 Q34361976-0DB88063-9B57-4B2D-8531-4972547DDC40 Q37711623-BFF7CA87-B88E-4E4D-986A-5F71F1238C2A Q37733073-45F87F42-6474-45B7-BCF1-DE23C63E7ECD Q38128358-71C24B92-F8C0-4E2B-805F-742FE3650159 Q38521775-9E54AED7-880A-483D-B861-96EB1336AD86 Q47169310-693DFC03-A4C9-4B2E-BDB7-89C25D8788B7

P2860

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

http://www.wikidata.org/entity/Q34231261

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@ast

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@en

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@nl

type

label

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@ast

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@en

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@nl

prefLabel

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@ast

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@en

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@nl

P1433

Q34231261-5AE2E879-0946-4F44-BDEC-9D3ED93A30CC

P1476

Q34231261-11F1B8F9-ABD4-4056-BD61-773C56F91B5A

P2093

Q34231261-1C9A340F-D0F0-4613-B828-49525E8E8020

Q34231261-3841C103-D8F6-4072-A02C-F25DD80ECA18

Q34231261-BE21C057-6408-4790-914E-F17E7584A9BA

Q34231261-CA417C7E-56ED-4119-8536-555796498236

Q34231261-E9A2E8FA-C6E2-433A-93D4-5E5B49955744

P2860

Q34231261-0882C229-6510-4357-A566-187D58AB7E78

Q34231261-27CDC24F-50D4-4717-B6BA-47622E05D952

Q34231261-36078CD2-52FD-41F3-9E24-F9B065AD64E0

Q34231261-49CC173B-5F7E-4328-A292-C3CCF122E90B

Q34231261-63526F7A-AB58-4652-9E2D-BC948BF9DEA7

Q34231261-67725B55-0A4C-422B-8793-88259702DF00

Q34231261-9C4DD1F3-7DE7-4A86-81EA-0A3BC7BD9F39

Q34231261-A438DE9A-CE14-49A0-83E2-C968B36A28C6

Q34231261-A9272130-9C94-4EA1-81D8-FAA8D8F57715

Q34231261-D528D36D-FCCE-4CA4-93D0-9BF5CAFC8771

P2888

Q34231261-3C2DAD0F-442E-46C6-B22D-C78E3E30021D

P304

Q34231261-1814E09B-D78E-4FCF-B726-6F4F4D3F1ACF

P31

Q34231261-350DC032-B5C5-42FF-B10D-4489FB1E120F

P356

Q34231261-0E4F4523-7BEB-43E0-BCBA-A47E8D463045

P433

Q34231261-FAE37695-EE01-4E86-82E9-94AC7AABA1C7

P478

Q34231261-E96DAE45-D4F9-42C8-84EA-2449C40B07FD

P577

Q34231261-F18AEB06-0C4D-4E10-932E-CC5493F9BB4A

P5875

Q34231261-6249EF00-C629-4069-8D3D-80915D5521C8

P6179

Q34231261-9C153D3D-7400-42A2-A6C1-28D3012218CF

P698

Q34231261-CA02EEA6-A3C4-4DD5-AEFE-4B6D7C409018

P932

Q34231261-9F6E804B-6A4F-48CF-B1B5-8AB5FA176319

P356

P1433

P1476

Phase I study of ON 01910.Na ( ...... refractory B-cell malignancies

@en

P2093

A Wiestner

http://www.w3.org/2001/XMLSchema#string

F Wilhelm

http://www.w3.org/2001/XMLSchema#string

G Aue

http://www.w3.org/2001/XMLSchema#string

M Farooqui

http://www.w3.org/2001/XMLSchema#string

M Roschewski

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity

Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.

Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.

P2888

P304

1920-1923

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.79

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236042811

http://www.w3.org/2001/XMLSchema#string

P6179

1003035399

http://www.w3.org/2001/XMLSchema#string

P698

23486532

http://www.w3.org/2001/XMLSchema#string

P932

4172371

http://www.w3.org/2001/XMLSchema#string